The phase 2b ENLIVEN trial, a multicenter, randomized, double-blind, placebo-controlled study, included 222 patients with biopsy-confirmed NASH and F2-F3 fibrosis, assigned to receive pegozafermin at doses of 15 mg weekly, 30 mg weekly, 44 mg every 2 weeks, or placebo for 24 weeks
However, before this can happen, researchers must first show that semaglutide is safe and effective for mental health in general
LIPO-B is not a weight-loss drug
Thin, smooth consistencies generally cause less discomfort than thick, heavy shakes
A comprehensive review in Pharmacological Research confirms that skeletal muscle changes with GLP-1 treatment appear to be adaptive, aligning with what you would expect given the amount of weight lost (Pereira et al., 2025)
They see the new body in the mirror but still feel like the old body